Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Schadendorf, Dirk; Long, Georgina V.; Stroiakovski, Daniil; Karaszewska, Boguslawa; Hauschild, Axel; Levchenko, Evgeny; Chiarion-Sileni, Vanna; Schachter, Jacob; Garbe, Claus; Dutriaux, Caroline; Gogas, Helen; Mandala, Mario; Haanen, John B. A. G.; Lebbe, Celeste; Mackiewicz, Andrzej; Rutkowski, Piotr; Grob, Jean-Jacques; Nathan, Paul; Ribas, Antoni; Davies, Michael A.; Zhang, Ying; Kaper, Mathilde; Mookerjee, Bijoyesh; Legos, Jeffrey J.; Flaherty, Keith T.; Robert, Caroline

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Autor(en):

Schadendorf, Dirk; Long, Georgina V.; Stroiakovski, Daniil; Karaszewska, Boguslawa; Hauschild, Axel; Levchenko, Evgeny; Chiarion-Sileni, Vanna; Schachter, Jacob; Garbe, Claus; Dutriaux, Caroline; Gogas, Helen; Mandala, Mario; Haanen, John B. A. G.; Lebbe, Celeste; Mackiewicz, Andrzej; Rutkowski, Piotr; Grob, Jean-Jacques; Nathan, Paul; Ribas, Antoni; Davies, Michael A.; Zhang, Ying; Kaper, Mathilde; Mookerjee, Bijoyesh; Legos, Jeffrey J.; Flaherty, Keith T.; Robert, Caroline

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

European Journal of Cancer (2017), Bd. 82, S. 45-55

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2017.05.033

ISSN:

1879-0852